Arrowhead refinances $400 million Sixth Street loan, cuts rate to SOFR plus 5.50%
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, replacing a 15.0% payment-in-kind facility with a $400.0 million term loan at three-month Term SOFR plus 5.50% that matures November 2, 2031. The existing loans were repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, a discount of about $68 million from the 2.0x MOIC payment otherwise owed, and the new terms remove required prepayments from plozasiran sales and licensing proceeds. For shareholders, the filing shows lower interest cost, a longer maturity and fewer mandatory repayments, while the company now carries a $400.0 million secured obligation.
Key points
- New $400.0 million senior secured term loan matures November 2, 2031, with interest at three-month Term SOFR (1.00% floor) plus 5.50%, versus a fixed 15.0% rate paid in kind on the retired loans
- Existing loans repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, which included a discount of about $68 million from the 2.0x MOIC payment
- Minimum unrestricted cash covenant reduced to $125.0 million from $150.0 million
- New agreement no longer requires prepayment from plozasiran sales, royalties, milestones or pipeline monetizations; the filing says the terms are to be filed with the 10-Q for the quarter ended December 31, 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:18 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.